Microwave-assisted synthesis, spectroscopic characterization, and biological evaluation of fused thieno[2,3-d]pyrimidines as potential anti-cancer agents targeting EGFRWT and EGFRT790M. 2023

Moustafa O Aboelez, and Moumen S Kamel, and Amany Belal, and Ahmed El Badry Abdel-Aziz, and Mohammed A S Abourehab, and H Abdel-Ghany, and Mohamed A El Hamd, and Mahmoud Abd El Aleem Ali El-Remaily
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag, 82524, Egypt. moustafaaboelez@pharm.sohag.edu.eg.

Epidermal growth factor receptor (EGFR) is a transmembrane protein tyrosine kinase that is usually overexpressed in many types of cancers. In the present study, an effort was done in synthesis of new 3,4-diaminothieno[2,3-b] thiophene-2,5-dicarbonitrile derivatives 2-8, assisted by a microwave device. Different spectroscopic instruments were used for their analysis and confirmed their chemical structures. The antimicrobial properties of the produced compounds were investigated and found to be promising. Next, they were tested for cytotoxicity against MCF-7, HepG-2, HCT-116, and A549 cell lines. Moreover, in vitro cytotoxicity evaluation against well-known standards, namely, gefitinib and erlotinib was achieved using MTT method. The obtained compounds (2-8) were found to be more effective against the two tested cancer cell lines than erlotinib. In MCF-7 and A549 cells, compound 3 was found to be 4.42 and 4.12 times more active than erlotinib, respectively. The activity of radical scavenging was inhibited by 78%. The most cytotoxic compounds were subsequently studied for their kinase inhibitory effect against EGFRWT and EGFRT790M using the HTRF assay. Compound 3 was shown to be the most powerful against both kinds of EGFR, with IC50 values of 0.28 and 5.02. Furthermore, compound 2 demonstrated the highest antioxidant activity as it has a radical scavenging activity of 78%. Compounds 2,6,7 and 8 revealed to be the most safe compounds, none hepatotoxic, none carcinogenic, none immunotoxic, none mutagenic and none cytotoxic.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008872 Microwaves That portion of the electromagnetic spectrum from the UHF (ultrahigh frequency) radio waves and extending into the INFRARED RAYS frequencies. EHF Waves,Extremely High Frequency Radio Waves,Micro Wave,Micro Waves,Ultrahigh Frequency Waves,Microwave Radiation,EHF Wave,Micro Waves,Microwave,Microwave Radiations,Radiation, Microwave,Ultrahigh Frequency Wave,Wave, EHF,Wave, Micro,Wave, Ultrahigh Frequency,Waves, Micro
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069347 Erlotinib Hydrochloride A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER. 11C-erlotinib,CP 358,774,CP 358774,CP-358,774,CP-358774,Erlotinib,Erlotinib HCl,N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine,OSI-774,Tarceva,11C erlotinib,358,774, CP,358774, CP,CP358,774,CP358774,HCl, Erlotinib,Hydrochloride, Erlotinib,OSI 774,OSI774
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Moustafa O Aboelez, and Moumen S Kamel, and Amany Belal, and Ahmed El Badry Abdel-Aziz, and Mohammed A S Abourehab, and H Abdel-Ghany, and Mohamed A El Hamd, and Mahmoud Abd El Aleem Ali El-Remaily
January 2015, Anti-inflammatory & anti-allergy agents in medicinal chemistry,
Moustafa O Aboelez, and Moumen S Kamel, and Amany Belal, and Ahmed El Badry Abdel-Aziz, and Mohammed A S Abourehab, and H Abdel-Ghany, and Mohamed A El Hamd, and Mahmoud Abd El Aleem Ali El-Remaily
January 2022, Molecules (Basel, Switzerland),
Moustafa O Aboelez, and Moumen S Kamel, and Amany Belal, and Ahmed El Badry Abdel-Aziz, and Mohammed A S Abourehab, and H Abdel-Ghany, and Mohamed A El Hamd, and Mahmoud Abd El Aleem Ali El-Remaily
December 2017, Chemical biology & drug design,
Moustafa O Aboelez, and Moumen S Kamel, and Amany Belal, and Ahmed El Badry Abdel-Aziz, and Mohammed A S Abourehab, and H Abdel-Ghany, and Mohamed A El Hamd, and Mahmoud Abd El Aleem Ali El-Remaily
January 1979, Archiv der Pharmazie,
Moustafa O Aboelez, and Moumen S Kamel, and Amany Belal, and Ahmed El Badry Abdel-Aziz, and Mohammed A S Abourehab, and H Abdel-Ghany, and Mohamed A El Hamd, and Mahmoud Abd El Aleem Ali El-Remaily
January 2016, Chemical & pharmaceutical bulletin,
Moustafa O Aboelez, and Moumen S Kamel, and Amany Belal, and Ahmed El Badry Abdel-Aziz, and Mohammed A S Abourehab, and H Abdel-Ghany, and Mohamed A El Hamd, and Mahmoud Abd El Aleem Ali El-Remaily
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Moustafa O Aboelez, and Moumen S Kamel, and Amany Belal, and Ahmed El Badry Abdel-Aziz, and Mohammed A S Abourehab, and H Abdel-Ghany, and Mohamed A El Hamd, and Mahmoud Abd El Aleem Ali El-Remaily
June 2010, Molecules (Basel, Switzerland),
Moustafa O Aboelez, and Moumen S Kamel, and Amany Belal, and Ahmed El Badry Abdel-Aziz, and Mohammed A S Abourehab, and H Abdel-Ghany, and Mohamed A El Hamd, and Mahmoud Abd El Aleem Ali El-Remaily
April 2010, European journal of medicinal chemistry,
Moustafa O Aboelez, and Moumen S Kamel, and Amany Belal, and Ahmed El Badry Abdel-Aziz, and Mohammed A S Abourehab, and H Abdel-Ghany, and Mohamed A El Hamd, and Mahmoud Abd El Aleem Ali El-Remaily
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Moustafa O Aboelez, and Moumen S Kamel, and Amany Belal, and Ahmed El Badry Abdel-Aziz, and Mohammed A S Abourehab, and H Abdel-Ghany, and Mohamed A El Hamd, and Mahmoud Abd El Aleem Ali El-Remaily
December 2013, Medicinal chemistry (Shariqah (United Arab Emirates)),
Copied contents to your clipboard!